EndoGastric Solutions, Inc., is a leader in incisionless procedural therapy for GERD.
EGS’ mission is to combine the most advanced concepts in gastroenterology and surgery to develop products and procedures that address unmet needs in gastrointestinal diseases.
EGS’ proprietary technology platform, the EsophyX® fastener delivery system, is designed to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. EGS is committed to further developing and commercializing innovative, evidence-based, incisionless surgical technology.
The original EsophyX device and SerosaFuse® fasteners were cleared by the FDA in 2007. The technology has continued to evolve with the launch of the company’s third generation device, the EsophyX Z device in 2015. The device is commercially available in the United States by both gastroenterologists and surgeons to treat GERD
The EsophyX device is used to perform the company’s TIF® procedure (Transoral Incisionless Fundoplication)—a surgical solution performed without the need for external incisions through the skin that enables physicians to reconstruct the gastroesophageal valve from within the stomach and correct the root cause of GERD.
|“It’s clear that patients suffering from GERD need an option beyond medication that masks the symptoms of the condition or an alternative to invasive surgery that over-corrects the anatomical cause.Based on the robust clinical evidence, I believe that the TIF® procedure using the EsophyX® device has the potential to bridge that gap, providing a viable, much-needed treatment option for millions of GERD sufferers.–Skip Baldino
President and CEO,